<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>Seaport Therapeutics, Inc. (SPTX) 表示，其增大规模的首次公开募股定价为每股 18 美元，共计 14.16 百万股，处于目标范围的最高点。</p>
<p>预计公司将从此次发行中筹集约 2.549 亿美元的总收入。它还授予承销商 30 天的选择权，以购买额外的 212 万股。</p>
<p>这些股票预计将于 2026 年 5 月 1 日在纳斯达克全球精选市场以 “SPTX” 代码开始交易，发行预计将于 2026 年 5 月 4 日结束。高盛、摩根大通、Leerink Partners、花旗集团和 Stifel 担任此次交易的联合账簿管理人。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做空纳斯达克生物技术 ETF - ProShares

标普生物技术 ETF - SPDR

<p>Seaport Therapeutics, Inc. 已将其增发的 1416 万股首次公开募股定价为每股 18 美元，筹集了约 2.549 亿美元。这些股票将于 2026 年 5 月 1 日在纳斯达克交易，股票代码为 "SPTX"，发行将于 2026 年 5 月 4 日结束。承销商有 30 天的选择权，可以额外购买 212 万股，承销商包括高盛、摩根大通等联合主承销商</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Seaport Therapeutics, Inc. (SPTX) said it has priced its upsized initial public offering of 14.16 shares at $18 per share, at the top of the target range.</p>
<div class="lb-trans"><p>Seaport Therapeutics, Inc. (SPTX) 表示，其增大规模的首次公开募股定价为每股 18 美元，共计 14.16 百万股，处于目标范围的最高点。</p>
</div><p>The company is expected to raise about $254.9 million in gross proceeds from the offering. It has also granted underwriters a 30-day option to purchase an additional 2.12 million shares.</p>
<div class="lb-trans"><p>预计公司将从此次发行中筹集约 2.549 亿美元的总收入。它还授予承销商 30 天的选择权，以购买额外的 212 万股。</p>
</div><p>The shares are set to begin trading on the Nasdaq Global Select Market on May 1, 2026 under the ticker &#34;SPTX&#34;, with the offering expected to close on May 4, 2026. Goldman Sachs, J.P. Morgan, Leerink Partners, Citigroup, and Stifel are serving as joint book-running managers for the deal.</p>
<div class="lb-trans"><p>这些股票预计将于 2026 年 5 月 1 日在纳斯达克全球精选市场以 “SPTX” 代码开始交易，发行预计将于 2026 年 5 月 4 日结束。高盛、摩根大通、Leerink Partners、花旗集团和 Stifel 担任此次交易的联合账簿管理人。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

Seaport Therapeutics Prices Upsized IPO Of 14.16 Mln Shares At $18 Each

rttnews

Invesco Nasdaq Biotechnology ETF

标普生物技术 3 倍做多 - Direxion

动态生物技术与基因组 ETF - Invesco

2 倍做多纳斯达克生物技术 ETF - ProShares

纽交所高增长板生物技术指数 ETF - First Trust

医药突破 ETF - ALPS

生物科技ETF基金

生物科技 ETF - VanEck Vectors

基因改革 ETF - ARK

纳斯达克 OMX 交易所

高盛

摩根大通

花旗

Stifel Financial

GS Hldg R

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

CITIGROUP INC 6.250 NON CUM SER II PFD WI

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Seaport Therapeutics 以每股 18 美元的价格为其扩大后的首次公开募股定价，共发行 1416 万股